WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, May 24, 2016

Throwing a punch at Parkinson's

May 24, 2016


I'm on the heavy bag, throwing left jabs, ignoring the relentless blare of Kanye's "Drive Slow, Homie" played at a volume that would raise the dead. I punch to a one-two count: left jab, right cross. I'm working as hard as I've ever worked, and even in this unheated gym I sweat as if it's a sauna. - Finally, the bell rings. It feels as if I've been at it for an hour; actually, three minutes have passed. The ensuing one-minute break seems to last four seconds. Let's be clear: Boxing, even when the opponent is only a heavy bag, is a brutal sport. But brutality is needed, even welcome, when you're facing a progressive, incurable neurological disease. I have Parkinson's disease, and it causes my body to just freeze up. Weirdly enough, boxing helps me get unstuck.
All 12 of us in this class bear the unmistakable signs of Parkinson's disease. I spot a dapper, cheerful white-haired fellow shaking like a leaf (tremor). Next, a balding, heavyset guy stumbling forward awkwardly on his toes (dystonia, or muscle cramping). Then I see myself in a mirror: a man in a white T-shirt, khaki shorts and Nike running shoes, standing still, seemingly paralyzed. I'm in the midst of a Parkinson's freeze (an extreme form of bradykinesia, or slow movement).
Although Parkinson's is generally thought of as an old-person's disease, I was diagnosed with a young-onset version 18 years ago, at age 35. Since then, I've taken every sort of medication known to science. I've had brain surgery - two tiny electrodes were implanted deep in my brain to stimulate an area affected by Parkinson's - which unquestionably has helped treat some of my symptoms. But medicine and surgery have not cured my freezing and falling, my gait and balance issues that worsen as my disease progresses: When walking across a busy street, I may suddenly, inexplicably come to a full stop as the light is about to change. Even the slightest downhill slope of a path causes me to fall forward.
Exercise, researchers have learned, is essential for Parkinsonians, and since being diagnosed I have embraced that therapy. But as time has gone on, my exercise options dwindled. After hundreds of falls, which left my knees more scar than skin, I gave up running. Frozen and jerky movements meant that tennis and skiing were no longer options. So last year, when I learned about a boxing program for people with Parkinson's, I had to investigate.
A decade ago, Scott Newman, an Indiana prosecutor and early-onset Parkinsonian, took up boxing and found it improved his agility and daily functioning. He eventually founded Rock Steady Boxing, a program for Parkinson's patients that now operates in 89 sites around the country, including the one I discovered last year in Los Angeles.

Research finds benefits
Boxing demands balance, timing, gait, speed and hand-eye coordination - all of which are challenged by Parkinson's. The Rock Steady program also encompasses other exercises, such as squat jumps, heel walking, agility drills, raised-knee walking, trampoline work, jumping rope and skipping. The boxing portion is noncontact, thankfully, and includes work on heavy bags and speed bags, and aiming punches at the moving targets provided by a trainer's padded "focus mitts."
Does boxing actually improve Parkinson's symptoms? A 2011 study in the journal of the American Physical Therapy Association looked at a small sampling of Parkinson's patients who participated in two to three 90-minute Rock Steady training sessions per week for nine months. The researchers found that the patients showed "short-term and long-term improvements in balance, gait, activities of daily living, and quality of life after the boxing training program." While these results can't be considered conclusive proof, the reported improvements mirror my own experience. Although I have not stopped freezing or falling, I do so less frequently, and my balance and gait seem to have improved.

Exactly why boxing workouts may help people with Parkinson's is not clear. The study noted that Rock Steady's "whole body approach" might be the key to its success, due to its "dynamic balance activities and multidirectional reaching and stepping ... agility drills within the circuit training regimen, such as jumping rope, and footwork activities, focused on the initiation of movement and fast-paced changes in direction." All help parts of the body affected by Parkinson's.
A 2013 review in Lancet Neurology made a compelling case for the role of exercise that incorporates "goal-based" components - where people need to pay constant attention to what their body is doing and make adjustments in response to external feedback. Boxing, tai chi, tango and similar activities, the review said, seem to improve the brain function of people with Parkinson's, which improves movement.

Ordinarily, human movement relies on the interaction of unconscious (automatic) and conscious (cognitive) control. But in Parkinson's, automatic control is diminished as nerve cells in an area of the brain that controls movement begin to die off and stop producing an important neurotransmitter called dopamine. This means that people with Parkinson's must make a conscious effort to accomplish such simple tasks as walking or lifting an object - things that healthy people do automatically. Parkinson's medications, such as synthetic dopamine, alleviate some motor symptoms. But their effectiveness is limited and they do not address the cognitive problems that many Parkinsonians can develop, which range from becoming easily distracted and disorganized to having trouble focusing or remembering words when speaking.
The brain has a remarkable ability to adapt to damage caused by disease or injury by growing new brain cells, the review noted, and goal-based exercise facilitates this ability. Boxing training is definitely goal-based. It forces my brain to think about and then make simple movements - such as walking, jogging, jumping, bending, reaching, stepping in all directions - that a healthy person does with no thought.

Rock Steady's training program has given me regular, hands-on practice in dealing with movement challenges, giving me more confidence. Boxing trains me to do things consciously that once came naturally: initiate movements from my core, move my legs and arms simultaneously, plan my next move, stay aware of my body's alignment and position to maintain balance.

Plagued by a fear of falling
What Parkinsonians call "balance confidence" is critical. It is fear of falling, rather than the falls themselves, that most limits my ability to perform the activities of daily living - to go to a restaurant, volunteer at my kids' schools, walk downhill. It is fear of falling that causes me to take tiny, rapid, uncontrolled steps or makes my feet freeze in place while my upper body keeps moving forward. It is fear that makes me do the very things that make me fall - and one does not need to have Parkinson's to know that the psychology of fear can drive us directly into what we want to avoid.

For many years, the only perceived link between boxing and Parkinson's was that the former caused the latter; in fact, Muhammad Ali, who took far too many punches, may be the world's most visible Parkinsonian. Today, a neurologist might actually prescribe boxing training - with no contact, of course - as therapy for Parkinson's.

So I pound away on the heavy bag, not training for a fight because I am already in the thick of one. It's a fight for my life.

http://health.einnews.com/article/327626100/KwpvDU5BbtFGGp7B

THE INCIDENCE OF PARKINSON'S DISEASE IS FALLING

May 24, 2016


Instead of Parkinson's Disease becoming progressively more common as was assumed, the incidence of Parkinson's Disease, which is the rate at which people are newly diagnosed, has been found to be continuously declining.

The incidence of Parkinson's disease and Parkinsonism were assessed by comparing data from 1990 until 2010, at 1990, 2000 and 2010. All factors were accounted for. 

The incidence of Parkinson's Disease in 2000 was found to be only 55% of what it was in 1990. The incidence of Parkinson's Disease in 2010 was found to be only 39% of what it was in 1990. The findings showed that the incidence of Parkinsonism in general, and of Parkinson's Disease in particular, decreased substantially between 1990 and 2011, and is continuously declining.

These findings can not indicate that the methods of treating Parkinson's Disease and Parkinsonism have improved because there was already a substantial decline at the point of diagnosis.

Reference : American Journal of Epidemiology [2016] Apr 29 [Epub ahead of print] (S.K. Darweesh, P.J.Koudstaal, B.H.Stricker, A.Hofman, M.A.Ikram)


Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/27188952


http://www.viartis.net/parkinsons.disease/news/160524.pdf mail@viartis.net
©2016 Viartis 

http://www.viartis.net/parkinsons.disease/news/160524.pdf

Monday, May 23, 2016

Spinal Cord Stimulator Dominates the Internal Neuromodulation Devices Market

May 23, 2016

A new report from Data Bridge Market Research delves deep into the global internal neuromodulation devices market.
This market is driven by the rising incidence of failed back surgeries, Parkinson’s disease, urinary incontinence, and other related indications. In addition, it is segmented into five product types: Spinal Cord Stimulator, Deep Brain Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator and Gastric Nerve Stimulator.
Per a media release from Data Bridge Market Research, the Spinal Cord Stimulator segment dominates the global internal neuromodulator devices market, followed by deep brain stimulator and vagus nerve stimulator.
In terms of geography, North America is the largest market for these devices, while the Asia-Pacific region is the fastest growing market due to the large incidence of Parkinson’s disease in Asian countries such as China.
For more information, visit Data Bridge Market Research.
http://www.rehabpub.com/2016/05/spinal-cord-stimulator-dominates-internal-neuromodulation-devices-market/

Parkinson’s disease therapy safinamide launches in the UK


 Author: Victoria White, Digital Content Producer
May 23, 2016

Safinamide is available for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other Parkinson’s disease medicines in mid-to late-stage fluctuating patients.

Safinamide is a new chemical entity with a unique mode of action including selective and reversible MAO-B-inhibition and blocking of voltage dependent sodium channels which leads to modulation of abnormal glutamate release. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, with data supporting this effect over 2 years. Results from 6 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Safinamide is a once-daily dose and has no diet restrictions.

Safinamide now available in eight countries
Commenting on the availability of the treatment, Andrew Lees, MD FRCP, FMedSci, Professor of Neurology, (The National Hospital for Neurology and Neurosurgery, Queen Square and Emeritus Director, Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology), said: “After 10 years with no new drugs for Parkinson’s disease I welcome the addition of another effective treatment option for patients.”

Maurizio Castorina, CEO of Zambon, added: “We are committed to developing innovative therapies for patients suffering from PD and other central nervous system diseases. Xadago offers PD patients a novel therapeutic option in the treatment of this progressive disease.”


The UK is the latest country launching safinamide, which is also available in seven other countries: Germany, Switzerland, Spain, Italy, Belgium, Denmark, and Sweden.

http://www.europeanpharmaceuticalreview.com/41218/news/industry-news/parkinsons-disease-safinamide/?

Atherosclerosis is Alzheimer's Disease of Blood Vessels, Study Suggests


In atherosclerosis, plaque builds up on the inner walls of arteries that deliver blood to the body. Studying mice and tissue samples from the arteries of patients, researchers at Washington University School of Medicine in St. Louis suggest this accumulation is driven, at least in part, by processes similar to the plaque formation implicated in brain diseases such as Alzheimer's and Parkinson's.


The study is published in the journal Science Signaling.
A look behind the scenes in the process of plaque accumulating in arteries, the new study is the first to show that another buildup is taking place. Immune cells attempting to counteract plaque formation begin to accumulate misshapen proteins. This buildup of protein junk inside the cells interferes with their ability to do their jobs.
Protein buildup is widely studied in the brain -- accumulation of proteins such as amyloid beta and tau are hallmarks of Alzheimer's, Parkinson's and other degenerative neurological disorders. But until now, the process of misshapen protein buildup within cells has not been implicated in atherosclerosis.
"In an attempt to fix the damage characteristic of atherosclerosis, immune cells called macrophages go into the lining of the arteries," said senior author Babak Razani, MD, PhD, assistant professor of medicine. "The macrophage is like a firefighter going into a burning building. But in this case, the firefighter is overcome by the conditions. So another firefighter goes in to save the first and is likewise overcome. And another goes in, and the process continues to build on itself and worsen."
The researchers showed that this protein buildup inside macrophages results from problems with the waste-disposal functions of the cell. They identified a protein called p62 that is responsible for sequestering waste and delivering it to cellular incinerators called lysosomes. To mimic atherosclerosis, the researchers exposed the cells to types of fats known to lead to the condition. The researchers noted that during atherosclerosis, the macrophages' incinerators become dysfunctional. And when cells stop being able to dispose of waste, p62 builds up. In a surprise finding, when p62 is missing and no longer gathers the waste in one place, atherosclerosis in mice becomes even worse.
Razani and his colleagues, including the study's first author, Ismail Sergin, PhD, a research assistant, also found these protein aggregates and high amounts of p62 in atherosclerotic plaque samples taken from patients, suggesting these processes are at work in people with plaque building up in the arteries.
"That p62 sequesters waste in brain cells was known, and its buildup is a marker for a dysfunctional waste-disposal system," Razani said. "But this is the first evidence that its function in macrophages is playing a role in atherosclerosis."
The study demonstrates that p62's role in gathering up the misfolded proteins is protective against atherosclerosis, even if the cell can't actually dispose of the waste it gathers.
"If p62 is missing, the proteins don't aggregate," Razani said. "It's tempting to think this might be good for the cell, but we showed this is actually worse. It causes more damage than if the waste were corralled into a large 'trash bin.' You can imagine a situation where lots of trash is being generated and see that it would be better to keep it all in one place, rather than have it strewn across the floor. You might have difficulty removing the trash to the dumpster, but at least it's contained."
In atherosclerosis, and perhaps in the brain disorders characterized by protein accumulation, such evidence suggests it would be better to focus on ways to fix the cells' waste-disposal system for getting rid of the large protein aggregates, rather than on ways to stop the aggregates from forming.
The above post is reprinted from materials provided by Washington University School of Medicine. Note: Materials may be edited for content and length.
Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.
Primary Resource:

I. Sergin, S. Bhattacharya, R. Emanuel, E. Esen, C. J. Stokes, T. D. Evans, B. Arif, J. A. Curci, B. Razani. Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis. Science Signaling, 2016; 9 (409): ra2 DOI:10.1126/scisignal.aad5614

Reviewed and Approved by a member of the DoveMed Editorial Board

Last updated: Feb. 2, 2016

Source: DoveMed
http://www.otjonline.com/news2016/05/news23a.php?

Inside the Sausage Factory of Drug Approval: Nuplazid (pimavanserin) coverage didn’t inspect closely enough




May 23, 2016


The FDA’s drug approval process was in the news earlier this month when Nuplazid (pimavanserin), a new drug to treat the hallucinations and delusions that sometimes accompany Parkinson’s disease, was approved.  Anyone knowing anything about FDA drug approvals knows how hard it is to predict outcomes after a lengthy and complicated process comprised largely of experts closely scrutinizing the minutiae of drug research data, and discussing those data in multiple and lengthy advisory committee meetings. Easily this could be likened to the making of sausages, where a wide variety of ingredients must pass through messy and largely opaque machinery before emerging in the form of a big capsule.

The squeamish would do well not to look too closely
And yet journalists have an obligation to translate the finer details of the drug approval process for news consumers. Nuplazid approval stories in STATFOX NewsHealthDay, and Reuters hit many of the main points but varied in the amount of detail provided. Few, for example, explained what the drug’s “breakthrough” status meant — even though the newly created designation is the primary basis of the drug’s speedy approval. We’ve seen stories about other new drugs that also neglect to clarify what that means.
As the FDA notes, a drug can qualify as a breakthrough — meaning it is eligible for expedited review — if it is:
  • intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition; and
  • preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
Approval based on a single small study
In this case, the “preliminary clinical evidence” supporting the drug’s approval consists of a single six-week study with 199 patients. Clearly this eyebrow-raising fact was glossed over by many news outlets (as well as by the company news release we reviewed by the drug’s manufacturer Acadia), and the stories left the breakthrough designation issue largely unchallenged. Some articles were thorough in summarizing the effects of the drug, but few questioned the clinical significance of a three-point change in a 9-point scale as reported in the Lancet. And there was little scrutiny of the fact that, compared with placebo, five times as many pimavanserin patients discontinued the drug during the trial because of adverse effects. The STAT story helpfully referred back to the FDA briefing documents, reminding us that for every two patients who are expected to achieve ‘much improved’ status as a result of Nuplazid, one patient experiences a serious adverse event.
A few stories, including a short one at FOX News included the important caveat that “Nuplazid will carry a boxed warning about the risks of death when used in older patients with dementia,” adding that “the drugs are not approved for that use.” HealthDay told us how small the one trial was and how much the drug is likely to cost: “expected to be priced at $13,500 per patient for a year.”  
There were, however, some unjustified (and unchallenged) statements in the reporting that might tend to paint the drug in too rosy a light. Marketwatch quoted Michael Okun, medical director of the National Parkinson Foundation, who said that the approval “represents a major paradigm shift in the treatment of Parkinson’s disease psychosis.” The only paradigm being shifted, in my opinion, is seeing a decisive 12-2 vote in favor of a drug that the FDA says must wear a black box warning, indicating it increases the risk of death in the demented elderly. Before quoting Okun’s cheerleading comments, MarketWatch would have done well to disclose that Okun’s foundation takes money from Acadia as well as several other drug companies.  
Patient advocate stresses potential for harm
One person who doesn’t share Okun’s enthusiasm is Kim Witczak, who knows a few things about the drug approval process and has attended many FDA advisory hearings over the years.  She was there as one of two consumer and patient representatives, watching as pimavanserin entered the sausage factory.
For her the key issue is the “breakthrough” designation, which the company achieved a few years ago and which allowed them to seek approval based on a single small study. She told me: “I was shocked about the lack of numbers in the clinical trial and what ‘breakthrough’ therapy designation really means.” In her opinion consumers and their doctors need to know a lot more about the drug approval process–and that the drug’s modest effects are counterbalanced by the potential for adverse effects. That’s why she voted against it, telling me: “For every two patients who had a 50% reduction in psychosis–a third has an adverse event.” 
Even though Nuplazid is required to carry the FDA-mandated Black Box warning that all the other antipsychotics are required to carry (warning of risk of death if used in the elderly with dementia), Witczak believes it will be used ‘off label’ for all kinds of things. She picked up that fact by listening closely to what the Wall Street analysts were saying about the drug, and listening in as the company’s CEO spoke to market analysts. She said: “Some analysts said the drug had a potential $2-$3 billion market ‘off-label’.” Which is to say the market could be massively expanded to millions of schizophrenics or patients with Alzheimer’s: Not bad for a drug that was taken for six weeks by 95 patients.
Shouldn’t physicians and consumers hear about the negative studies?
Journalists can learn a lot about drug approvals in the US, a process which starts with the FDA’s Center for Drug Evaluation and Research (CDER) and its team of “physicians, statisticians, chemists, pharmacologists, and other scientists.” Those experts review the presented data, and the proposed labeling to establish if a drug’s health benefits outweigh its potential harms. The FDA advisory committee process then exposes that evidence to hearings containing consumer, academic and industry experts, who can further interrogate the data, a process that is largely open to the public.
For Susan Molchan, a geriatric psychiatrist who is on the board of the National Physician’s Alliance and is an expert in dementia in the elderly, the reporting of this drug approval had a key fact omitted: the issue of publication bias.  That’s when studies, usually negative ones, don’t get published or publicized and so their results aren’t factored into the larger body of evidence on a drug. A drug company could conceivably conduct any number of studies to demonstrate the effect of their drugs, and eventually they’ll get one that looks good. In the case of this new drug to treat Parkinson’s there were at least two other failed studies, as indicated in the FDA documentation. The real bias, she says, is that “we’re only hearing about the positive one, and the negative ones are buried.”  She added, “This is a big flaw, and with the ‘breakthrough’ designation they only require minimal research, often just one clinical trial with few people on the drug.”  The bias induced by buried studies would suggest the drug is even less effective than it appears. 
Dr. Molchan often treats Parkinson’s patients with these types of symptoms and the first thing she tries to do is reduce the doses of the dopamine drugs like L-DOPA or Sinemet. She wondered how this new drug would fare against the existing comparators such as lower doses of dopamine drugs or the antipsychotic Seroquel which is often used in these patients.  
Physicians misunderstand what FDA approval really means
Long-time journalists who report on the FDA know it’s very hard for the agency to say “no” to approving a new drug, especially when there is no existing treatment for a particular disease. There is strong pressure to provide access to new medicines. However, FDA officials might be a bit more hesitant to green-light every breakthrough, game changer and paradigm shift that comes along if they knew how much their reports influenced consumers, and most importantly, physicians. According to this article in the Journal of the American Medical Association, (behind a paywall but reported here in Medscape) a sizeable majority (73%) “of the physicians incorrectly believed FDA approval meant the effectiveness of the drug was similar to the effectiveness of other approved drugs.”  And 70%” incorrectly believed both statistically significant and clinically significant effects were required for FDA approval.”
That misunderstanding has “consequences,” according to Drs. Lisa Schwartz and Steve Woloshin who designed this survey. They write that the fact physicians don’t understand the drug approval process “may lead physicians to overprescribe newly approved drugs—particularly breakthrough therapies—and inadequately communicate how well these drugs work to the patients who will use them.”  
And that’s something we should all feel a little squeamish about.​
http://www.healthnewsreview.org/2016/05/inside-the-sausage-factory-of-drug-approval-nuplazid-pimavanserin-coverage-didnt-inspect-closely-enough/?

Now, a device for early detection of cancer, Alzheimer’s, Parkinson’s diseases

A team of researchers has come up with a biosensor that is capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.


May 23, 2016
A team of researchers has come up with a biosensor that is capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Developed by researchers at the National Nanotechnology Laboratory (LNNano), the device is basically a single-layer organic nanometer-scale transistor on a glass slide. It contains the reduced form of the peptide glutathione (GSH), which reacts in a specific way when it comes into contact with the enzyme glutathione S-transferase (GST), linked to Parkinson’s, Alzheimer’s and breast cancer, among other diseases.
The GSH-GST reaction is detected by the transistor, which can be used for diagnostic purposes.
The project focuses on the development of point-of-care devices by researchers in a range of knowledge areas, using functional materials to produce simple sensors and microfluidic systems for rapid diagnosis.
Researcher Carlos Cesar Bof Bufon explained that platforms like this one can be deployed to diagnose complex diseases quickly, safely and relatively cheaply, using nanometer-scale systems to identify molecules of interest in the material analyzed.
In addition to portability and low cost, the advantages of the nanometric biosensor include its sensitivity in detecting molecules, according to Bufon.
He noted that this is the first time organic transistor technology has been used in detecting the pair GSH-GST, which is important in diagnosing degenerative diseases, for example, adding that it can detect such molecules even when they’re present at very low levels in the examined material, thanks to its nanometric sensitivity.
The system can be adapted to detect other substances, such as molecules linked to different diseases and elements present in contaminated material, among other applications. This requires replacing the molecules in the sensor with others that react with the chemicals targeted by the test, which are known as analytes.
The study appears in the journal Organic Electronics.
http://www.financialexpress.com/article/lifestyle/health/now-a-device-for-early-detection-of-cancer-alzheimers-parkinsons/263035/?

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease

May 23, 2016

OTC Disclosure & News Service

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease


IRVINE, Calif.May 23, 2016 
Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO") for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
Cryoport, Inc. Logo.
Two of Cryoport's strategically located depots, in southern California and Singapore, will provide logistics support for the clinical study from ISCO's research facility in California to the study site in Australia. As the premier cryogenic logistics provider, Cryoport's extensive experience with the movement of high-value biologic material for clinical trials and commercialization programs globally gives ISCO's team assurance that its shipment will arrive with fully documented chain of custody and chain of condition data.
"This trial will take place across the globe and it is imperative that our cell therapy maintains integrity. We are pleased to have Cryoport handle our global logistics requirements," said Russell Kern, PhD, Executive Vice President and Chief Scientific Officer of ISCO. 
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "Cryoport is proud to work with ISCO and support its efforts. We are fully confident in our ability to manage the logistics of the therapies as specified – and with certainty. We look forward to furthering our relationship with ISCO as we move forward."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Supporting the entire lifecycle of therapies from clinical trials to approval and commercialization, the Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.        
Forward Looking Statements 
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

SOURCE Cryoport, Inc.